Cognition Therapeutics Inc
CGTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001455365
No open-market purchases or sales by Cognition Therapeutics Inc insiders were filed in the last 90 days; 66 institutions reported holding it in 13F filings for Q2 2026, worth $26.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −9 vs. previous quarter
- 66
- 13F valueReported value at the end of Q2 2026
- $26.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CGTX, Q2 2026
No superinvestor reported holding CGTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cognition Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Doyle John BrendanChief Financial Officer | PPurchase | +10.0K | $1.13 | +$11.3K | +1.6%627.5K after | |
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Ricciardi LisaCEO & President | PPurchase | +9.18K | $1.10 | +$10.1K | +0.5%1.72M after | |
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Caggiano AnthonyChief Medical Officer | PPurchase | +10.0K | $1.11 | +$11.1K | +1.2%874.9K after | |
| Feb 4, 2025 (view filing) | Jan 31 | 4 days | Ricciardi LisaCEO & President | PPurchase | +38.9K | $0.77 | +$29.9K | New position38.9K after | |
| Mar 14, 2024 (view filing) | Mar 14 | Same day | Ricciardi LisaCEO & President | PPurchase | +5.70K | $1.75 | +$9.97K | +2.0%291.3K after | |
| Nov 29, 2022 (view filing)7:02 AM ET | Nov 28 | 1 day | BIOS Memory SPV I, LP and 9 othersDirector, 10% Owner | PPurchase | +16.1K | $2.65 | +$42.6K | +5.5%309.7K after | 3 lotsDuplicate filing |
| Nov 29, 2022 (view filing)7:00 AM ET | Nov 28 | 1 day | BIOS Memory SPV II, LP and 8 othersDirector, 10% Owner | PPurchase | +16.1K | $2.65 | +$42.6K | +5.5%309.7K after | 3 lots |
| Nov 29, 2022 (view filing) | Nov 29 | Same day | Richstone Ellen BDirector | PPurchase | +10.0K | $2.66 | +$26.6K | New position10.0K after | |
| Nov 17, 2022 (view filing)7:00 AM ET | Nov 16 | 1 day | Fletcher Aaron G.L. and 9 othersDirector | PPurchase | +71.0K | $1.40 | +$99.4K | +30.0%307.9K after | 3 lotsDuplicate filing |
| Nov 17, 2022 (view filing)7:00 AM ET | Nov 16 | 1 day | Kreis Leslie W. and 8 othersDirector | PPurchase | +71.0K | $1.40 | +$99.4K | +30.0%307.9K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cognition Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 6,000,000 | $6.90M | 16.56% | 00.0% | Unchanged |
| Davenport & Co LLC | 4,259,511 | $4.90M | 0.02% | +1,366,703+47.2% | Added |
| Vanguard Capital Management LLC | 3,438,775 | $3.95M | 0.00% | +436,988+14.6% | Added |
| BlackRock, Inc. | 1,261,993 | $1.45M | 0.00% | +293,631+30.3% | Added |
| Chescapmanager LLC | 997,029 | $1.15M | 0.15% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 910,006 | $1.05M | 0.00% | −10,202−1.1% | Reduced |
| Renaissance Technologies LLC | 693,288 | $797.3K | 0.00% | −423,848−37.9% | Reduced |
| Hilton Capital Management, LLC | 548,950 | $631.3K | 0.04% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 508,220 | $584.5K | 0.00% | +44,536+9.6% | Added |
| CM Management, LLC | 450,000 | $517.5K | 0.33% | +50,000+12.5% | Added |